Videos

Tetracycline-class antibiotic, omadacycline (Nuzyra), is FDA approved for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), and is also being studied for other potential indications.

In Part 2 of a video interview, Sornana Segal-Maurer, MD, discusses the newly published research findings that detail the potential of lenacapavir.

The company's investigational vaccine, which is in a phase 3 study, is an example of its commitment to addressing these viruses.

Could lenacapavir be the answer for people with multidrug-resistant HIV infection? Principal investigator Sorana Segal-Maurer discusses the promising trial results in this challenging cohort (Interview part 1).

These behind-the-scenes, essential personnel remain a significant part of health care and is a field with growth opportunities, but remain a field in need of public awareness to enable its stability.

These paramount medical personnel behind the scenes are facing staffing challenges that could be bordering on a national crisis in public health.

With an evolving understanding of T-cells in immunity and emerging SARS-Co-V2 strains, evaluating these vital protection cells can offer researchers insights into response and how to develop future therapies and vaccines.

April 10 is a day that commemorates a population group that is emerging in terms of increased incidence rates, and needs help with inherent challenges including medication adherence and understanding of the disease.

Being displaced by war is causing a disruption in treatment and long-term health care for Ukrainians. And it is likely, the situation will become more dire as the country’s public infrastructure worsens.

The Center for Global Development is launching a new working group, which aims to address antimicrobial resistance by exploring how to improve incentives for pharmaceutical companies to develop new antimicrobials for low-income and middle-income countries (LMICs).

Tori Pipak, a physician assistant at Allegheny Health Network’s Positive Health Clinic, details the comprehensive services the clinic provides to people living with HIV.

Congress’s spending bill allocated drastically less funding for HIV testing, prevention, and treatment than previously promised. Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, explains why it is so vital to continue the fight against HIV.

A new virtual program aims to train clinicians and other providers on terminology and how to engage patients in effective dialogue and counseling.

Axcella Therapeutics chief medical officer Dr. Margaret Koziel discusses the stage 2a clinical trial for their novel long covid treatment.

This week, one of the m-RNA COVID-19 vaccine’s effectiveness was shown to drop from 68% to 12% in children 5-11 years old within a month. This data raises concerns of what should be done to protect this pediatric population.

A clinician offers his perspective on how the virus is behaving and the role that vaccines and therapies will play.

Investigators looked at myocardial infarction risks over several years within 2 health care systems examining both people with HIV (PWH) and people without HIV (PWoH).

The investigational therapy has demonstrated promising results utilizing subcutaneous injections every 6 months.

After presenting at CROI 2022, Dr. Jessica Justman discusses her community-level survey findings: COVID-19 infections do not vary by age.

Investigators looked at full vaccination and booster dose observational data to offer some insights on protection and breakthrough infections.

Data shown in the Pinetree clinical trial and being presented with 2 posters at CROI demonstrate both benefits and safety in preventing progression to more severe disease.

Boston’s Fenway Health looked at testing and prevention trends during 3 phases of the COVID-19 pandemic.

A process known as thin film freezing can convert existing therapies into powder that offers another delivery solution and may help alleviate storage challenges in developing countries.

The company recently submitted its data to the federal regulatory authorities for an Emergency Use Authorization of its COVID-19 vaccine, NVX-CoV2373. As it's time to think about this potential vaccine being available in the US, clinicians offer some insights and perspective on it.

In utilizing a modeling study, investigators estimated reductions in HIV incidence rates as well as PrEP usage rates and viral suppression across US cities over 10 years.

A predictive tool, POC Advisor, has been developed to support faster diagnosis and intervention of this dangerous condition.

During a continuation of a difficult time in our history, overwhelmed providers need to take a step back and find time for themselves to unwind and destress from COVID-19.

The award given to the research institute by the state of Pennsylvania looks to delve deep in understanding vulnerable populations and taking some lessons away in addressing future potential pandemics.